Influence of epilobium angustifolium extract on 5α-reductase type 2 and mapk3 kinase gene expression in rats prostates

1. Elterman DS, Lawrentschuk N, Guns E, Hersey K, Adomat H, Wood CA, Fleshner N. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with α-blockers and 5α-reductase inhibitors. J Urol 2010; 183(5):2085-9.10.1016/j.juro.2009.12.097Search in Google Scholar

2. Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol 2013; 20(1):28-39.10.1111/iju.12008Search in Google Scholar

3. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002; 12(1):15-8.10.1097/00042307-200201000-00004Search in Google Scholar

4. Von Löw EC, Perabo FG, Siener R, Müller SC. Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 2007; 21(2):189-204.Search in Google Scholar

5. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2008; 179(6):2119-25.PDR for Herbal Medicines. 4th ed. Thompson Healtcare Inc., USA 2007:903-4.Search in Google Scholar

6. Van-Hellemont J. Compedium de Phytotherapie. Association Pharmaceutique, Brussels 1986.Search in Google Scholar

7. Wichtl M. Herbal Drug and Phytopharmaceuticals, 3th ed. Medpharm GmbH, Stuttgart 2004.Search in Google Scholar

8. Hevesi BT, Houghton PJ, Habtemariam S, Kery A. Antioxidant and anti-inflammatory effect of Epilobium parviflorum. Schreb Phytother Res 2009; 23(5):719-24.10.1002/ptr.2725Search in Google Scholar

9. Kujawski R, Bartkowiak-Wieczorek J, Ożarowski M, Bogacz A, Cichocka J, Karasiewicz M, Mrozikiewicz PM. Studies on phytochemical profile of plant materials and extracts derived from aerial parts of Epilobium sp. - a minireview. Herba Pol 2011; 57(4):25-34.Search in Google Scholar

10. Stolarczyk M, Naruszewicz M, Kiss AK. Extracts from Epilobium sp. herbs induce apoptosis in human hormone-dependent prostate cancer cells by activating the mitochondrial pathway. J Pharm Pharmacol 2013; 65(7):1044-54.10.1111/jphp.12063Search in Google Scholar

11. Hevesi TB, Blazics B, Kery A. Polyphenol composition and antioxidant capacity of Epilobium species. J Pharm Biomed Anal 2009; 15;49(1):26-31.10.1016/j.jpba.2008.09.047Search in Google Scholar

12. Bazylko A, Kiss AK, Kowalski J. High-performance thin-layer chromatography method for quantitative determination of oenothein B and quercetin glucuronide in aqueous extract of Epilobii angustifolii herba. J Chromatogr A 2007; 30;1173(1-2):146-50.10.1016/j.chroma.2007.10.019Search in Google Scholar

13. Kiss A, Kowalski J, Melzig MF. Effect of Epilobium angustifolium L. extracts and polyphenols on cell proliferation and neutral endopeptidase activity in selected cell lines. Pharmazie 2006; 61(1):66-9.Search in Google Scholar

14. Granica S, Bazylko A, Kiss AK. Determination of macrocyclic ellagitannin oenothein B in plant materials by HPLC-DAD-MS: method development and validation. Phytochem Anal 2012; 23(6):582-7.10.1002/pca.2358Search in Google Scholar

15. Hiermann A. Bucar F. Studies of Epilobium angustifolium extracts on growth of accessory sexual organs in rats. J Ethnopharmacol 1997; 55(3):179-83.10.1016/S0378-8741(96)01498-5Search in Google Scholar

16. Vitalone A, Bordi F, Baldazzi C, Mazzanti G, Saso L, Tita B. Anti-proliferative effect on a prostatic epithelial cell line (PZ-HPV-7) by Epilobium angustifolium L. Farmaco 2001; 56(5-7):483-9.10.1016/S0014-827X(01)01067-9Search in Google Scholar

17. Vitalone A, McColl J, Thome D, Costa LG, Tita B. Characterization of the effect of Epilobium extracts on human cell proliferation. Pharmacology 2003; 69(2):79-87.10.1159/00007236012928581Search in Google Scholar

18. Ramstead AG, Schepetkin IA, Quinn MT, Jutila MA. Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFNγ production by lymphocytes. PLoS One 2012; 7(11):e50546.10.1371/journal.pone.0050546351155723226309Search in Google Scholar

19. Krakurt S, Semiz A, Celik G, Gencler-Ozkan AM. Sen A. Adali O. Epilobium hirsutum alters xenobiotic metabolizing CYP1A1, CYP2E1, NQO1 and GPx activities, mRNA and protein levels in rats. Pharm Biol 2013; 51(5):650-8.10.3109/13880209.2012.76240423527956Search in Google Scholar

20. Stolarczyk M, Piwowarski JP, Granica S, Stefańska J, Naruszewicz M, Kiss AK. Extracts from Epilobium sp. Herbs, Their Components and Gut Microbiota Metabolites of Epilobium Ellagitannins, Urolithins, Inhibit Hormone-Dependent Prostate Cancer Cells-(LNCaP) Proliferation and PSA Secretion. Phytother Res 2013; doi:10.1002.10.1002/ptr.494123436427Search in Google Scholar

21. Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med 2013; 21(3):172-9.10.1016/j.ctim.2013.01.00723642948Search in Google Scholar

22. Kujawski R, Bogacz A, Derebecka-Hołysz N, Cichocka J, Kujawski J, Mikołajczak PŁ, Bobkiewicz- Kozłowska T, Grześkowiak E, Krajewska-Patan A, Czerny B, Mrozikiewicz PM. Medicinal plants from Epilobium genus - biological and pharmacological properties. Herba Pol 2010; 56(1):66-82.Search in Google Scholar

23. Lesuisse D, Berjonneau J, Ciot C, Devaux P, Doucet B, Gourvest JF, Khemis B, Lang C, Legrand R, Lowinski M, Maquin P, Parent A, Schoot B, Teutsch G. Determination of oenothein B as the active 5-α-reductaseinhibiting principle of the folk medicine Epilobium parviflorum. J Nat Prod 1996; 59(5):490-2.10.1021/np960231c8778238Search in Google Scholar

24. Ducrey B, Marston A, Göhring S, Hartmann RW, Hostettmann K. Inhibition of 5 α-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species. Planta Med 1997; 63(2):111-4.10.1055/s-2006-9576249140222Search in Google Scholar

25. Kujawski R, Mrozikiewicz PM, Bogacz A, Cichocka J, Mikołajczak PŁ, Czerny B, Bobkiewicz-Kozłowska T, Grześkowiak E. Influence of standardized extract of Epilobium angustifolium on estrogen receptor α and β expression in in vivo model. Ginekol Pol 2010; 81(8):600-605.Search in Google Scholar

26. Kiss A, Kowalski J, Melzig MF. Compounds from Epilobium angustifolium inhibit the specific metallopeptidases ACE, NEP and APN. Planta Med 2004;70(10):919-23.10.1055/s-2004-83261715490319Search in Google Scholar

27. Foradori CD, Werner SB, Sandau US, Clapp TR, Handa RJ. Activation of the androgen receptor alters the intracellular calcium response to glutamate in primary hippocampal neurons and modulates sarco/ endoplasmic reticulum calcium ATPase 2 transcription. Neuroscience 2007; 149:155-164.10.1016/j.neuroscience.2007.06.05417870249Search in Google Scholar

28. Benett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 2010; 42(6):813-27.10.1016/j.biocel.2009.11.01319931639Search in Google Scholar

29. Linja MJ, Porkka K, Kang Z, Savinainen KJ, Janne OA, Tamela TL, Vessella RL, Palvimo JJ, Visakorpi T. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10(3):1032-40.10.1158/1078-0432.CCR-0990-3Search in Google Scholar

30. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120(4):719-33.10.1002/ijc.22365Search in Google Scholar

31. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011; 82(4-5):84-99.10.1016/j.diff.2011.04.006Search in Google Scholar

32. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G. Androgen receptor mediates nongenomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 2004; 279(15):14579-86.10.1074/jbc.M306143200Search in Google Scholar

33. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009; 63(2):142-8.10.1016/j.maturitas.2009.03.008Search in Google Scholar

34. Iehlé C, Délos S, Guirou O. et al. Human prostatic steroid 5 α-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54:273-279.10.1016/0960-0760(95)00134-LSearch in Google Scholar

35. Carson CIII, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urolog. 2003; 61(Suppl. 1):2-7.10.1016/S0090-4295(03)00045-1Search in Google Scholar

36. Gravas S, Oelke M. Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010; 28(1):9-15.10.1007/s00345-009-0493-y280931419956956Search in Google Scholar

37. Kosowicz J, Miskowiak B, Konwerska A, Belloni AS, Nussdorfer GG, Malendowicz LK. Pneumadin in the rat ventral prostate and its hormonal regulation. Hormon. Metab. Res 2004; 36:78-81.Search in Google Scholar

38. Schepetkin IA, Kirpotina LN, Jakiw L, Khlebnikov AI, Blaskovich CL, Jutila MA, Quinn MT. Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium. J Immunol 2009; 183(10):6754-66. 10.4049/jimmunol.0901827278354619846877Search in Google Scholar

39. Kiss AK, Bazylko A, Filipek A, Granica S, Jaszewska E, Kiarszys U, Kośmider A, Piwowarski J. Oenothein B’s contribution to the anti-inflammatory and antioxidant activity of Epilobium sp. Phytomedicine 2011; 18(7):557-60.10.1016/j.phymed.2010.10.01621112753Search in Google Scholar

40. Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG. Inhibition of rat α-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997; 61:55-64.10.1016/S0960-0760(97)00002-2Search in Google Scholar

41. Kang DI, Chung JL. Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol 2013; 54(4):213-9.10.4111/kju.2013.54.4.213Search in Google Scholar

42. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47:53-8.10.1046/j.1365-2125.1999.00843.xSearch in Google Scholar

43. Stuart JD, Lee FW, Simpson Noel D, Kadwell SH, Overton LK, Hoffman CR, Kost TA, Tippin TK, Yeager RL, Batchelor KW, Bramson HN. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol 2001; 62:933-42.10.1016/S0006-2952(01)00728-6Search in Google Scholar

44. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y. Saturable binding of finasteride to steroid 5α-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet 2010; 25:208-13. 10.2133/dmpk.25.20820460827Search in Google Scholar

• Chemical profiles and biological activities of acetone extracts of Curcuma xanthella
• Geranyl flavanone from Feronia limonia (L.) Swingle
• Evaluation of detoxification of aflatoxin-b1 by using Ag nanoparticles of oil extracts user prepared by using some medical herbs
• Synthetic seeds technology of Salvia officinalis as a method for short-term storage and in vitro propagation of valuable genotypes
• Morphological and biochemical responses of selected Ocimum species under drought